Modern View on the Pathogenetic Therapy of Diabetic Polyneuropathy
Journal Title: Міжнародний ендокринологічний журнал - Year 2014, Vol 7, Issue 63
Abstract
The article deals with the treatment of diabetic polyneuropathy (DPN) using Actovegin. The results of research on the effectiveness of this drug in 200 patients with diabetes mellitus (aged from 19 to 88 years) are provided. As a result of pathogenetic therapy with Actovegin, it was able to reduce the severity of DPN — 32 % of patients with severe diabetic neuropathy moved to a group of patients with moderate DPN.
Authors and Affiliations
N. O. Pertseva, I. N. Mikhailinchik
Keywords
Related Articles
- EP ID EP229565
- DOI -
- Views 49
- Downloads 0
Lifestyle Change as a Part of Complex Therapy of Chronic Systemic Inflammation in Metabolic Syndrome
From a perspective of integrative physiology, metabolic syndrome (MS) can be regarded as a syntropy of internal diseases, based on the systemic inflammation, insulin resistance, lipotoxicity and other processes which dep...
Peculiarities of disturbances of the functional renal state in the early period of experimental diabetes mellitus
Background. The purpose of our research was a comparative analysis of specificity and severity of kidney dysfunction in the early period of alloxan- and streptozotocin-induced diabetes mellitus. Materials and methods. Th...
Violations of the System of Lipid Peroxidation in Type 2 Diabetes Mellitus (Literature Review)
The review presents the data on the current state of the problem of diabetes mellitus type 2 and the role of oxidative stress. Over the last decade, the number of patients with diabetes mellitus has increased by more tha...
Prevalence, Risk Factors and Complications of Diabetes Insipidus in the Republic of Uzbekistan
Despite the fact that diabetes insipidus (DI) is a rare independent disorder, there are many publications on this subject in the contemporary literature. Interest to the problem of DI is due to the fact that the syndrome...
ORIGIN Trial (Background, Results)
ORIGIN — the longest and most extensive study on Lantus® use in patients with cardiovascular risk with diabetes mellitus (DM) type 2 in the early stages, as well as prediabetes, in which insulin therapy is not indicated...